Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:47:25.057Z.
Calculation as of: 2026-10-06T15:47:25.057Z.
Quote observation: 2026-10-06T15:38:42.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 75157c8a62e3fe86a7e5d9b3960d4dd2a79ae28b02be5cac6a633fb547f90e56
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Jyong Biotech Ltd. Ordinary Shares
Market Cap
$159.28M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$158.09M
Price/OCF Ratio
N/A
TTM Avg
78.89
3Y Avg
78.89
5Y Avg
78.89
Market Cap
$155.61M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$154.46M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$164.54M
Price/OCF Ratio
N/A
TTM Avg
193.13
3Y Avg
193.13
5Y Avg
37.46
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jyong Biotech Ltd. Ordinary Shares (MENS) | $159.28M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $159.02M | N/A | 113.17 | 139.63 | 64.33 |
| Minerva Neurosciences, Inc. (NERV)vs › | $158.09M | N/A | 78.89 | 78.89 | 78.89 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $155.61M | N/A | N/A | N/A | N/A |
| PepGen Inc. (PEPG)vs › | $163.59M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $154.46M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $164.54M | N/A | 193.13 | 193.13 | 37.46 |
| Quanterix Corporation (QTRX)vs › | $165.00M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $152.20M | N/A | 32.64 | 32.64 | 32.64 |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.98M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
